Countless concerned parents have asked the WCH about the new RSV vaccines. In this post, we look at what they are, as well as the virus itself, with the aim of helping readers make their own informed decisions. The post is in two parts. First, a summary of the most salient points. Then, a more academic paper into the context and science for health professionals and others looking to gain a deeper perspective.
Part 1: The “TLDR” Summary
[Note: “TDLR” is an abbreviation for “too long; didn’t read.” It is used to indicate that one didn’t read the whole text or to indicate that what follows is a summary of the overly long text.]
- RSV symptoms are mild and mimic the common cold. Most babies have been infected with RSV by their second birthday. In the EU, more than 90% of hospitalised adult RSV patients are over 65 years old.
- It is easily treated with nebuliser therapy. Urgent care and hospitalisation can occur for serious cases and if treated early, infant mortality should not be a concern. Among the 22.4 million children under 5 years old in the US, the annual risk of RSV hospitalisation is well under 1%.
- RSV “vaccines” only reduce the risk of hospitalisation from RSV by 1%.
- So-called RSV “vaccines” fall into three categories: monoclonal antibodies, a protein-based “vaccine,” and mRNA technology.
- The monoclonal antibody treatment is called nirsevimab and is given in a single dose. There are serious safety concerns around nirsevimab. The clinical trials had limitations and there is little to no long-term safety data. Ambiguity around its classification also complicates safety monitoring and accountability.
- Some reports link nirsevimab to infant deaths. Many treated infants still end up in hospital, and resistant strains of the virus are emerging. Antibody-dependent enhancement (“ADE”) is also a concern.
- Recent vaccines developed by GSK and Pfizer for pregnant women have shown a 2% increase in premature births and higher rates of neonatal deaths in trials.
- Moderna’s mResvia mRNA vaccine is recommended by the European Medicines Agency for the over-sixties, yet with no data showing it’s either safe or effective. The same safety concerns exist for mResvia as for any other mRNA “vaccine,” namely myocarditis, auto-immunity, genomic integration and cancer.
- There are alternatives. Studies show a clear inverse relationship of severity of RSV symptoms and vitamin D levels. Better vitamin D levels may lower the incidence of RSV-associated bronchiolitis in infants, and vitamin D helps enhance immune response, reduce inflammation and helps stop RSV getting into cells. Quercetin and zinc are also worth consideration as part of a treatment protocol.
If you’d like to discuss these points with your doctor or other health professional, consider sharing the following detailed paper with them. It includes aspects many vaccinating doctors have not been informed about so please discuss it with them before potential injections.
Hellbound and Down 